CIBC Asset Management Inc cut its stake in Humana Inc. (NYSE:HUM) by 4.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,748 shares of the insurance provider’s stock after selling 820 shares during the period. CIBC Asset Management Inc’s holdings in Humana were worth $4,080,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in HUM. Creative Planning raised its stake in shares of Humana by 0.3% in the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after acquiring an additional 15 shares during the last quarter. Aperio Group LLC raised its stake in shares of Humana by 24.0% in the second quarter. Aperio Group LLC now owns 106,571 shares of the insurance provider’s stock worth $25,643,000 after acquiring an additional 20,614 shares during the last quarter. Hengehold Capital Management LLC bought a new position in shares of Humana in the second quarter worth about $209,000. Bedrijfstakpensioenfonds Voor DE Media PNO bought a new position in shares of Humana in the second quarter worth about $2,219,000. Finally, Sit Investment Associates Inc. raised its stake in shares of Humana by 0.3% in the second quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock worth $2,892,000 after acquiring an additional 40 shares during the last quarter. 96.15% of the stock is owned by institutional investors.
In other Humana news, insider William Kevin Fleming sold 3,071 shares of Humana stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the transaction, the insider now directly owns 7,681 shares of the company’s stock, valued at approximately $1,927,777.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Elizabeth D. Bierbower sold 9,786 shares of Humana stock in a transaction on Friday, September 1st. The stock was sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the transaction, the insider now directly owns 18,042 shares in the company, valued at $4,672,878. The disclosure for this sale can be found here. Insiders sold a total of 20,660 shares of company stock valued at $5,319,600 in the last quarter. 0.80% of the stock is currently owned by company insiders.
Shares of Humana Inc. (NYSE HUM) opened at $233.28 on Thursday. The firm has a market cap of $34,223.56, a price-to-earnings ratio of 20.44, a PEG ratio of 1.65 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61. Humana Inc. has a one year low of $186.25 and a one year high of $264.56.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.12. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. Humana had a net margin of 3.49% and a return on equity of 15.99%. Humana’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.18 EPS. analysts expect that Humana Inc. will post 11.63 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be paid a $0.40 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.69%. Humana’s dividend payout ratio is currently 12.59%.
Several equities research analysts have commented on the stock. ValuEngine raised shares of Humana from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. BidaskClub downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Zacks Investment Research downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Piper Jaffray Companies upped their target price on shares of Humana to $280.00 and gave the company an “overweight” rating in a research note on Thursday, August 3rd. Finally, Cowen and Company reiterated an “outperform” rating and issued a $275.00 price target (up previously from $230.00) on shares of Humana in a report on Wednesday, September 20th. Thirteen investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $252.81.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.